Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 14 | 2024 | 1717 | 1.530 |
Why?
|
| Vancomycin | 5 | 2024 | 78 | 1.490 |
Why?
|
| Outpatients | 5 | 2024 | 370 | 1.210 |
Why?
|
| Teicoplanin | 2 | 2021 | 15 | 0.920 |
Why?
|
| Adenosine Monophosphate | 1 | 2024 | 63 | 0.880 |
Why?
|
| Alanine | 1 | 2024 | 142 | 0.860 |
Why?
|
| Ritonavir | 2 | 2023 | 73 | 0.840 |
Why?
|
| Organ Transplantation | 2 | 2024 | 228 | 0.790 |
Why?
|
| beta-Lactamases | 1 | 2022 | 41 | 0.750 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 10 | 0.730 |
Why?
|
| Aspergillosis | 1 | 2021 | 20 | 0.730 |
Why?
|
| Candidiasis | 1 | 2021 | 56 | 0.720 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 221 | 0.690 |
Why?
|
| Antiviral Agents | 3 | 2024 | 712 | 0.670 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2023 | 352 | 0.630 |
Why?
|
| Staphylococcal Infections | 2 | 2021 | 393 | 0.610 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 790 | 0.600 |
Why?
|
| Blood Coagulation Factors | 1 | 2018 | 53 | 0.590 |
Why?
|
| Hospitalization | 4 | 2024 | 2070 | 0.540 |
Why?
|
| Sepsis | 1 | 2020 | 574 | 0.440 |
Why?
|
| Hemorrhage | 1 | 2018 | 678 | 0.430 |
Why?
|
| Critical Illness | 1 | 2019 | 758 | 0.410 |
Why?
|
| Kidney | 2 | 2023 | 1385 | 0.410 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 711 | 0.400 |
Why?
|
| Cephalosporins | 2 | 2024 | 40 | 0.400 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 253 | 0.350 |
Why?
|
| Retrospective Studies | 14 | 2024 | 14518 | 0.340 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 601 | 0.330 |
Why?
|
| Humans | 28 | 2024 | 129650 | 0.290 |
Why?
|
| Adult | 11 | 2024 | 35576 | 0.230 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2024 | 18 | 0.230 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2024 | 8 | 0.230 |
Why?
|
| Health Care Rationing | 1 | 2024 | 57 | 0.220 |
Why?
|
| Aminoglycosides | 1 | 2024 | 23 | 0.220 |
Why?
|
| Cystitis | 1 | 2024 | 22 | 0.220 |
Why?
|
| beta-Lactams | 2 | 2023 | 28 | 0.220 |
Why?
|
| Tetracyclines | 1 | 2023 | 9 | 0.220 |
Why?
|
| Immune Reconstitution | 1 | 2023 | 6 | 0.210 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 42 | 0.210 |
Why?
|
| Endocarditis | 1 | 2024 | 37 | 0.210 |
Why?
|
| Acinetobacter Infections | 1 | 2022 | 12 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 3 | 2024 | 1367 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 1040 | 0.200 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 18 | 0.200 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 99 | 0.190 |
Why?
|
| Pseudomonas Infections | 1 | 2024 | 221 | 0.190 |
Why?
|
| Mycobacterium abscessus | 1 | 2023 | 107 | 0.190 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 44 | 0.190 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 149 | 0.190 |
Why?
|
| Aged | 8 | 2024 | 22103 | 0.190 |
Why?
|
| Creatinine | 2 | 2023 | 491 | 0.180 |
Why?
|
| Clostridium Infections | 1 | 2022 | 64 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 189 | 0.180 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2024 | 347 | 0.180 |
Why?
|
| Daptomycin | 1 | 2021 | 18 | 0.180 |
Why?
|
| Plasmids | 1 | 2022 | 358 | 0.180 |
Why?
|
| Antifungal Agents | 1 | 2021 | 129 | 0.170 |
Why?
|
| Salvage Therapy | 1 | 2021 | 134 | 0.170 |
Why?
|
| Burns | 1 | 2023 | 286 | 0.160 |
Why?
|
| Machine Learning | 1 | 2024 | 443 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 67 | 0.160 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2024 | 71 | 0.160 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2023 | 352 | 0.150 |
Why?
|
| Middle Aged | 7 | 2024 | 31154 | 0.150 |
Why?
|
| Vitamin K | 1 | 2018 | 40 | 0.150 |
Why?
|
| Hemostatics | 1 | 2018 | 49 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 573 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 566 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2017 | 51 | 0.140 |
Why?
|
| Colorado | 2 | 2024 | 4421 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2017 | 234 | 0.130 |
Why?
|
| Male | 10 | 2024 | 63681 | 0.120 |
Why?
|
| Bacterial Proteins | 1 | 2022 | 835 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 2742 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2024 | 10230 | 0.120 |
Why?
|
| Graft Survival | 1 | 2017 | 512 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 738 | 0.110 |
Why?
|
| Logistic Models | 1 | 2019 | 1988 | 0.110 |
Why?
|
| Female | 9 | 2024 | 68776 | 0.110 |
Why?
|
| Graft Rejection | 1 | 2017 | 598 | 0.110 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 1053 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1902 | 0.100 |
Why?
|
| Transplant Recipients | 2 | 2024 | 162 | 0.100 |
Why?
|
| Risk Factors | 3 | 2024 | 9765 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2017 | 721 | 0.090 |
Why?
|
| Standard of Care | 2 | 2022 | 72 | 0.090 |
Why?
|
| Bacteremia | 2 | 2024 | 197 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2704 | 0.080 |
Why?
|
| Subcutaneous Tissue | 1 | 2024 | 22 | 0.060 |
Why?
|
| Skin Transplantation | 1 | 2024 | 84 | 0.050 |
Why?
|
| Viremia | 1 | 2024 | 131 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2023 | 70 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 204 | 0.050 |
Why?
|
| Piperacillin | 1 | 2023 | 8 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 198 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 23 | 0.050 |
Why?
|
| Minocycline | 1 | 2022 | 27 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 154 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2022 | 340 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2023 | 203 | 0.050 |
Why?
|
| Health Policy | 1 | 2024 | 353 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2024 | 299 | 0.050 |
Why?
|
| Gentamicins | 1 | 2021 | 54 | 0.040 |
Why?
|
| Rifampin | 1 | 2021 | 85 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 265 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 371 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 711 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 173 | 0.040 |
Why?
|
| Skin | 1 | 2024 | 725 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 1007 | 0.040 |
Why?
|
| Incidence | 1 | 2024 | 2644 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2024 | 975 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 857 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1502 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 1156 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 20393 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1269 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2024 | 7133 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 1896 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2883 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 12426 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 5762 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 3973 | 0.020 |
Why?
|
| Infant | 1 | 2017 | 9024 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 10517 | 0.010 |
Why?
|
| Child | 1 | 2017 | 20883 | 0.010 |
Why?
|